CAD testing before kidney transplant does not reduce death rate and early MI: JAMA
California: An original investigation published in JAMA Internal Medicine has concluded that pretransplant Coronary Heart Disease (CHD) testing is not associated with reduced early posttransplant death or acute Myocardial Infarction (MI) in kidney transplantation.
The researchers from the Division of Nephrology at Stanford University School of Medicine have challenged the ubiquity of CHD testing before kidney transplant, which should be confirmed in interventional studies.
CHD testing candidates before transplant (in candidates of asymptomatic kidney transplant) is widespread. Various professional societies endorse this. However, there needs to be more data on how it is associated with perioperative outcomes.
Cheng et al. and colleagues did a study to answer the question, Does CHD testing before kidney transplant reduces early posttransplant death or MI?
The study points are:
- The study included 79334 adults, first-time kidney transplant recipients (January 2000-December 2014), in the US Renal Data System with at least one year of Medicare enrollment before and after the transplant.
- In the study, instrumental variable (IV) analysis was used.
- The exposure included nonurgent invasive or noninvasive CHD testing during the 12 months preceding the kidney transplant.
- The researchers measured the composite of death or acute MI within 30 days as the primary outcome.
- The participants were 38 % women, 21% Black and 61% White individuals with a mean age of 56.
- The primary outcome occurred in 4604 patients.
- The percentage of death and acute MI was 2.6% and 2.9%.
- The CHD testing rate was 56% among most test-intensive transplant programs and 24% in patients in the least test-intensive transplant program. (2012-2014)
- In the main IV analysis, CHD testing was not associated with a change in primary outcome rate, having a rate difference of 1.9%.
- The results were similar across study periods, except for 2000 -2003, during which CHD testing was associated with a higher event rate having a rate difference, of 6.8%.
To conclude, CHD testing before a kidney transplant may not be tied to reduced adverse outcomes early after the transplant.
Further reading:
Cheng XS, et al. Association of Pretransplant Coronary Heart Disease Testing With Early Kidney Transplant Outcomes. JAMA Intern Med. doi:10.1001/jamainternmed.2022.6069
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.